Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- FDA Pushes Back Decision on Hunter Syndrome Gene Therapy
August 20, 2025
- Santen Secures Asia Rights to RemeGen’s VEGF/FGF Eye Drug RC28-E
August 20, 2025
- Foreign Pharma Sales in Japan Projected to Rise 1.8% in 2025: Fuji Keizai
August 20, 2025
- Alloy Japan Looks to Turn iCAR-T into Shared Infrastructure, IND Filing Slated for 2026
August 20, 2025
- Marubeni Expands Pharma Sales Biz into Africa with Phillips Investment
August 20, 2025
- Daiichi Sankyo Snares First FDA Breakthrough Tag for ADC I-DXd
August 20, 2025
- Keytruda Retains Top Spot in Japan Drug Market in April-June: IQVIA
August 20, 2025
- Mounjaro Wins Double Crown in June GP Promotion: Intage
August 20, 2025
- Dalton Signals Plan to Lift ASKA Stake to 30%; Board Weighs Countermeasures
August 19, 2025
- MSD Rolls Out Airwin and Welireg in Japan
August 19, 2025
- AGs Identified for 4 Brands in Latest Generic Approvals, Including Bonviva and Epadel
August 19, 2025
- Mochida’s Low-Dose Lialda to Hit Shelves in September
August 19, 2025
- Espha to Launch Authorized Generic of Zytiga in December
August 19, 2025
- Eisai Launches Dayvigo in China, First Orexin Antagonist for Insomnia
August 19, 2025
- Sawai to Invest 19.5 Billion Yen to Strengthen Supply Capacity at Trust Pharmatech
August 19, 2025
- Padcev-Keytruda Combo Delivers Positive PIII Data in Bladder Cancer
August 18, 2025
- J&J’s New Bispecific Antibody Talvey Now Available in Japan
August 18, 2025
- Solasia Out-Licenses Cancer Drug to Singapore Firm Covering 19 Countries
August 18, 2025
- Mounjaro Tops Reps Detailing Chart in GP Market: Intage May Data
August 18, 2025
- Ultragenyx Japan Seeks Conditional Approval of Triheptanoin for LC-FAOD
August 12, 2025
ページ
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…